Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014

Details for Mechanism ID: 7142
Country/Region: Kenya
Year: 2013
Main Partner: Chemonics International
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $3,793,423

The overall objective of the Kenya Pharma project is to establish and operate a safe, secure, reliable and sustainable supply chain management system to forecast, quantify, procure, store and distribute pharmaceuticals, supplies and equipment needed to provide care and treatment of persons with HIV/AIDS in Kenya.

The strategy is to become more cost efficient over time. The project is constantly seeking opportunities to increase its cost efficiency through improved freight forwarding and improved delivery operations. The project also operates a competitive tender process for HIV/AIDS commodities with low cost being the most heavily weighted selection criterion.

Over time, a second strategy is to transition to the partner government, local organization or other donor. The Kenya Pharma project has sustainability as one of its overall program goals and is structured to maximize the use of Kenyan institutions and individuals in its provision of services. Kenya Pharma has been working with local suppliers and testing laboratories to increase the capacity of these institutions. Kenya Pharma is also in the process of becoming ISO 9001 certified to create a complete documentary file of operations for the use of any successor organization. Kenya Pharma has previously purchased 3 vehicles but does not plan to purchase any in FY12. This activity supports GHI/LLC and is funded primarily through pipeline funds in this budget cycle.

Funding for Care: Adult Care and Support (HBHC): $0

The Kenya Pharma project procures OI drugs for provision to implementing care and support programs within Kenya. The programs operate mostly at the facility level and target the spectrum of HIV/AIDS populations. The project supplies national coverage both through direct distribution and through stock sharing with the GoK-supported distribution system. The commodity aspects of the programs are continually monitored and evaluated using data collected from regular monthly facility-level patient, stock, and distribution reports; internal distribution records from the Kenya Pharma project; and direct customer feedback from partners and service providers (collected through a network of Kenya Pharma field representatives).

Funding for Care: Orphans and Vulnerable Children (HKID): $0

Resources requested in this budget area directly support the Let's Live Campaign to ensure that orphans and vulnerable children due to HIV/AIDS have access to zinc tablets. These resources will be coupled with those from other accounts which will support other children (who do not fall into the OVC category) to receive similar services across targeted areas.

Funding for Prevention: Injecting and Non-Injecting Drug Use (IDUP): $820,000

Kenya Pharma procure Methadone for IDU combination prevention. The intervention will include weaning off Injecting Drug Users from injecting drug use through treatment with Methadone which will be done through selected public and private facilities by UNODC. Kenya Pharma will liaise with the Ministry of Health to quantify and control the distribution of the methadone.

Funding for Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT): $2,686,423

The Kenya Pharma project procures ARVs consistent with the nationally recommended guidelines for the provision of PMTCT. All ARVs are, of course, USFDA tentatively or fully approved and also registered with the Kenya Pharmacy and Poisons Board. The project participates as an active member of the Commodity Security Committee (coordinated by NASCOP, the Kenyan HIV/AIDS coordinating body) and participates in national quantification and procurement planning exercises. The project is coordinating and collaborating with other members of the supply chain community to improve the data associated with the location and client populations of PMTCT service providers and also to put in place mechanisms to ensure that these data can be maintained in a sustainable manner in the future.

Funding for Treatment: ARV Drugs (HTXD): $287,000

The Kenya Pharma project procures the entire list of nationally recommended first line and second line ARVs for both adult and pediatric use. All ARVs are, of course, USFDA tentatively or fully approved and also registered with the Kenya Pharmacy and Poisons Board. The project also procures a limited list of OI drugs (antibiotics, antifungals, etc.) and drugs for co-infected TB patients. The project participates as an active member of the Commodity Security Committee (coordinated by NASCOP, the Kenyan HIV/AIDS coordinating body) and participates in national quantification and procurement planning exercises. There have been no stockouts of ARVs provided by the project in the last year and the project actively monitors stocks at all levels of the supply chain and coordinates among other members of the supply chain and among implementing partners to avoid future stockouts.

Subpartners Total: $0
DHL Exel: NA
Phillips Pharmaceuticals: NA
Vimta Labs: NA